21 December 2012
Elan Announces Completion of Demerger of Prothena Corporation plc| click here for the IRS Form 8937 - Report of Organizational Actions Affecting Basis of Securities & Information Statement
DUBLIN--(BUSINESS WIRE)--Dec. 21, 2012-- Elan Corporation, plc (NYSE:ELN) today announced completion of the separation of a substantial portion of its drug discovery business (the Prothena Business) into a new independent, publicly traded company, Prothena Corporation plc (Prothena). Prothena, which is incorporated in Ireland, today commenced trading on the NASDAQ Global Ma... |
|
19 December 2012
Elan Announces Availability of Information Statement in Respect of Prothena Corporation plc| DUBLIN--(BUSINESS WIRE)--Dec. 19, 2012--
Elan Corporation, plc (NYSE: ELN) announces that the information
statement in respect of Prothena Corporation plc, which is being
provided to holders of record of Elan ordinary shares and ADSs as of
December 14, 2012 and which describes the separation and distribution of
the Prothena Business in detail and contains important business and
financial information about Prothena, has been published. The
info... |
|
14 December 2012
Elan Announces Expected Timetable in Respect of Implementation of Proposed Demerger| DUBLIN--(BUSINESS WIRE)--Dec. 14, 2012--
Elan Corporation, plc (NYSE: ELN) today announced the expected timetable
of the separation of a substantial portion of its drug discovery
business (the Prothena Business) into a new independent, publicly traded
company, Prothena Corporation plc (Prothena). The separation will be
effected pursuant to a demerger under Irish law.
Under the demerger, Elan will transfer the Prothena Business to Prothena
... |
|
12 December 2012
Resolution to Approve the Prothena Business Demerger Passed at Elan EGM| DUBLIN--(BUSINESS WIRE)--Dec. 12, 2012--
Elan Corporation, plc (NYSE: ELN) announces that, at an Extraordinary
General Meeting (EGM) held earlier today, the sole ordinary resolution
to approve the demerger of the Prothena Business was duly passed. The
full text of the resolution was included in the notice of the EGM dated
November 12, 2012 which is available on the Company’s website. The
details of the votes lodged by proxy are also available on www.... |
|
05 December 2012
Elan Announces Record Date in Respect of Proposed Demerger| DUBLIN--(BUSINESS WIRE)--Dec. 5, 2012--
Elan Corporation, plc (NYSE: ELN) announced today that it has
established 11.59 p.m. (Dublin time) on December 14, 2012 as the record
date in connection with its previously announced separation of a
substantial portion of its drug discovery business into a new
independent, publicly traded company, Prothena Corporation plc
(Prothena), which separation will be effected pursuant to a demerger
under Irish la... |
|
27 November 2012
Elan Announces Enrollment of First Patient in Phase 2 Study of ELND005 (Scyllo-inositol) for the Treatment of Agitation/Aggression in Patients with Alzheimer's Disease|
Approximately 90% of AD patients develop neuropsychiatric symptoms
Approximately 60% of AD patients develop agitation/aggression
DUBLIN--(BUSINESS WIRE)--Nov. 27, 2012--
Elan Corporation, plc (NYSE: ELN) today announced that it has enrolled
the first patient in a Phase 2 clinical trial of ELND005 (Study AG201)
for the treatment of agitation/aggression in patients with moderate to
severe Alzheimer’s disease ... |
|
13 November 2012
Elan Announces Publication of EGM Circular in Respect of Proposed Demerger| DUBLIN--(BUSINESS WIRE)--Nov. 13, 2012--
Elan Corporation, plc (NYSE: ELN) today announced the publication and
filing of a circular to shareholders convening an extraordinary general
meeting (“EGM”) to be held in the Davenport Hotel, 8/10 Merrion Street
Lower, Dublin 2, Ireland at 10.00 a.m. on Wednesday, December 12, 2012
at which a resolution in connection with the proposed demerger of Elan’s
Neotope business (now referred to as the Prothena Busine... |
|
24 October 2012
Elan Reports Third Quarter 2012 Financial Results|
Revenues up 10%; Adjusted EBITDA up 38%;
13% increase in patients on Tysabri in last 12 months;
Neotope spin-off creating two separate entities on track.
DUBLIN--(BUSINESS WIRE)--Oct. 24, 2012--
Elan Corporation, plc today reported its third quarter and first nine
months 2012 financial results.
“The third quarter was an active one for Elan on a number of fronts.”
said Mr. Ke... |
|
23 October 2012
Elan Announces Expiration of Cash Tender Offer and Consent Solicitation for 8.75% Senior Notes due 2016| DUBLIN--(BUSINESS WIRE)--Oct. 23, 2012--
Elan Corporation, plc (“Elan”) (NYSE: ELN) announced today the
expiration and final results of the cash tender offer and consent
solicitation (the “Tender Offer and Consent Solicitation”), commenced on
September 24, 2012, by its wholly-owned subsidiaries, Elan Finance
public limited company (“Elan Finance”) and Elan Finance Corp. (“Elan
Corp.” and together with Elan Finance, the “Co-Issuers”), to purchase
... |
|
11 October 2012
TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MS|
Data demonstrate TYSABRI effect on Annualized Relapse Rates and EDSS
scores over 4 years
A pooled analysis report TYSABRI effect on fatigue at 12 months
Long-term safety data presented are consistent with current TYSABRI
labeling
WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Oct. 11, 2012--
Today, Biogen
Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced
t... |
|
10 October 2012
Elan Announces Webcast of Third Quarter 2012 Financial Results| DUBLIN--(BUSINESS WIRE)--Oct. 10, 2012--
Elan Corporation, plc (NYSE: ELN) announced today that it will host a
conference call on Wednesday, October 24, 2012 at 8:30 a.m. Eastern Time
(ET), 1:30 p.m. British Summer Time (BST) with the investment community
to discuss Elan’s third quarter 2012 financial results, which will be
released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously b... |
|
08 October 2012
Elan Announces Results Through Consent Payment Deadline of Cash Tender Offer and Consent Solicitation for 8.75% Senior Notes Due 2016| DUBLIN--(BUSINESS WIRE)--Oct. 8, 2012--
Elan Corporation, plc (“Elan”) (NYSE: ELN) announced today the results,
as of 11:59 p.m., Eastern time, on October 5, 2012 (the “Consent Payment
Deadline”), of the cash tender offer and consent solicitation (the
“Tender Offer and Consent Solicitation”), commenced on September 24,
2012, by its wholly-owned subsidiaries, Elan Finance public limited
company (“Elan Finance”) and Elan Finance Corp. (“Elan Corp.” and... |
|
01 October 2012
Elan Announces Redemption of Its Senior Notes Due 2016| DUBLIN--(BUSINESS WIRE)--Oct. 1, 2012--
Elan Corporation, plc (“Elan”) (NYSE: ELN) announced today that it will
redeem all of the Senior Notes due 2016 issued on October 2, 2009 (the
“2009 Notes”) and Senior Notes due 2016 issued on August 17, 2010 (the
“2010 Notes” and, together with the 2009 Notes, the “Notes”) of its
wholly owned subsidiaries, Elan Finance public limited company and Elan
Finance Corp. (the “Co-Issuers”), that remain outstanding fo... |
|
25 September 2012
Elan Announces Intent to Offer US$500 Million in Aggregate Principal Amount of Senior Notes Due 2019| DUBLIN--(BUSINESS WIRE)--Sep. 25, 2012--
Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced that its
wholly-owned subsidiaries, Elan Finance public limited company (“Elan
Finance”) and Elan Finance Corp. (“Elan Corp.” and together with Elan
Finance, the “Issuers”), intend to offer, subject to market conditions,
US$500 million in aggregate principal amount of Senior Notes due 2019
(the “Notes”). The Notes will be offered to qualified instituti... |
|
25 September 2012
Elan Announces Pricing of $600 Million 2019 Senior Notes| DUBLIN--(BUSINESS WIRE)--Sep. 25, 2012--
Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced the pricing
of the offering of US$600 million aggregate principal amount of 6.250%
Senior Notes due 2019 (“Notes”) by its wholly-owned subsidiaries, Elan
Finance public limited company and Elan Finance Corp. The Notes will be
issued at par. The offering is expected to close on October 1, 2012,
subject to customary closing conditions. The Notes will be ... |
|
24 September 2012
Elan Announces Commencement of Tender Offer and Consent Solicitation| DUBLIN--(BUSINESS WIRE)--Sep. 24, 2012--
Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced that its
wholly-owned subsidiaries, Elan Finance public limited company (“Elan
Finance”) and Elan Finance Corp. (“Elan Corp.” and together with Elan
Finance, the “Issuers”), are commencing a cash tender offer (the “Tender
Offer”) to purchase any and all of their outstanding:
8.750% Senior Notes due 2016 issued October 2, 2009 (the “20... |
|
20 September 2012
Elan Announces the Appointment of Hans Peter Hasler as Chief Operating Officer| DUBLIN--(BUSINESS WIRE)--Sep. 20, 2012--
Elan Corporation, plc (NYSE:ELN) today announced the appointment of Hans
Peter Hasler as Chief Operating Officer (“COO”) of the Company with
effect from October 1, 2012. Mr. Hasler is currently a non-executive
director of the Company and on his appointment as COO, he will retire
from the board of directors of the Company. Mr. Hasler was appointed a
director of Elan in September 2011. He is currently the chairm... |
|
29 August 2012
Elan Announces Dosing of First Patient in Phase 2 Trial of ELND005 (Scyllo-inositol) in Bipolar Disorder| DUBLIN--(BUSINESS WIRE)--Aug. 29, 2012--
Elan Corporation, plc (NYSE:ELN) today announced that it has commenced a
Phase 2, placebo-controlled, safety and efficacy study of oral ELND005
as an adjunctive maintenance treatment in patients with Bipolar I
Disorder (BPD 1) to delay the time to occurrence of mood episodes. The
first patient has been dosed in the study.
Bipolar I Disorder (BPD 1) is a severe form of BPD, also commonly known
as... |
|
13 August 2012
Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders|
Creates two independent, unique companies
Transaction aligns assets, timelines, and risk/reward
Elan to become immediately profitable and a high growth company
Targeting $1.00 earnings per share by 2015 with new business
construct
Commitment to science by providing initial capital to Neotope
Biosciences plc
Completion of transaction expe... |
|
06 August 2012
Elan Announces Johnson & Johnson Release of Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) In Mild to Moderate Alzheimer’s Disease|
Elan’s near term funding obligations to Janssen AI expected to
decrease
Elan to write down its equity method investment in Janssen AI
Elan focused on Tysabri growth and continued financial strengthening
DUBLIN--(BUSINESS WIRE)--Aug. 6, 2012--
Elan Corporation, plc (NYSE:ELN) announced today that Johnson & Johnson
has issued a press release regarding the discontinuation of Phase 3
... |
|
25 July 2012
Elan Reports Second Quarter and First Half 2012 Financial Results| DUBLIN--(BUSINESS WIRE)--Jul. 25, 2012--
Elan Corporation, plc today reported its second quarter and first half
2012 financial results.
“Progress continued during the course of the second quarter,” said Mr.
Kelly Martin, chief executive officer. “Underlying strength in the
Tysabri business was driven by continued adoption of the assay on a
global basis, which established the clinical framework to enable
additional net new patients to b... |
|
23 July 2012
Elan Announces Pfizer's Release of A Top-Line Result In First Of Four Bapineuzumab Phase 3 Trials| DUBLIN--(BUSINESS WIRE)--Jul. 23, 2012-- Elan Corporation, plc (NYSE:ELN) announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI. The press release can be accessed on http://www.pfizer.com/news/press_releases/pfizer_press_release.jsp?guid=20120723006412en&source=RSS_2011&page=1
As referenced in the Pfizer announcement, Study 302 is the first of four placebo-controlled Phase 3 studies to complete a ... |
|
12 July 2012
Elan Announces Webcast of Second Quarter 2012 Financial Results| DUBLIN--(BUSINESS WIRE)--Jul. 12, 2012--
Elan Corporation, plc (NYSE: ELN) announced today that it will host a
conference call on Wednesday, July 25, 2012 at 8:30 a.m. Eastern Time
(ET), 1:30 p.m. British Summer Time (BST) with the investment community
to discuss Elan’s second quarter 2012 financial results, which will be
released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously bro... |
|
11 July 2012
Elan-UCD endowment honours Irish business leaders and boosts Ireland's capacity in the 'Business of Biotechnology'| DUBLIN--(BUSINESS WIRE)--Jul. 11, 2012-- University College Dublin (UCD) and Elan Corporation plc, (NYSE: ELN) today announced two scholarships and an annual lecture series at University College Dublin (UCD) in the 'Business of Biotechnology' named in honour of Kieran McGowan, former head of the Industrial Development Authority of Ireland (IDA), Kyran McLaughlin, deputy chairman of Davy Stockbrokers and Laurence Crowley, the well-known accountant and board member of many Irish companies and... |
|
28 May 2012
Elan to Present at Jefferies 2012 Global Healthcare Conference| DUBLIN--(BUSINESS WIRE)--May. 28, 2012--
Elan Corporation, plc (NYSE: ELN) announced today that it will present
at the Jefferies 2012 Global Healthcare Conference on Monday, June 4th
at 9:30am Eastern Daylight Time (EDT), 2:30pm British Summer Time (BST).
Interested parties may access a live audio webcast of the presentation
by visiting the Investor Relations section of the Elan website at http://www.elan.com,
then clicking on the event icon.... |
|
17 May 2012
New Analysis of Risk Stratification for TYSABRI® Published in New England Journal of Medicine|
- Use of Biomarker has Potential to Advance Personalized Treatment
for MS Patients -
WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--May. 17, 2012--
Biogen
Idec (NASDAQ: BIIB) and Elan
Corporation, plc (NYSE: ELN) today announced that the New England
Journal of Medicine published research from the companies’ global
risk management program that updates the risk of TYSABRI®
(natalizumab)-associated progressive multifocal leukoencephalopa... |
|
27 April 2012
Elan to Present at Deutsche Bank 37th Annual
Healthcare Conference| DUBLIN, Apr 27, 2012 (BUSINESS WIRE) --Elan Corporation, plc (NYSE: ELN) announced today that it will present
at the Deutsche Bank 37th Annual Healthcare Conference on
Tuesday, May 8, 2012 at 10.40 a.m. Eastern Standard Time, 3:40pm
Greenwich Mean Time.
Interested parties may access a live audio webcast of the presentation
by visiting the Investor Relations section of the Elan website at http://www.elan.com,
then clicking on the event icon. Following th... |
|
26 April 2012
Elan Reports First Quarter 2012 Financial Results| DUBLIN, Apr 26, 2012 (BUSINESS WIRE) --Elan Corporation, plc, today reported its first quarter 2012 financial
results.
"Our first quarter financial performance was solid and represents a good
start to the year across all aspects of our business," said Mr. Kelly
Martin, chief executive officer. "We continue to build the business by
delivering double digit top line growth, continuously strengthening our
balance sheet and simultaneously investing in our un... |
|
26 April 2012
New TYSABRI Data Presented at 64th Annual
AAN Meeting Highlight Biogen Idec & Elan Commitment to Improving
Outcomes in Multiple Sclerosis| -- Preliminary Results from TYNERGY Study Measure Impact of TYSABRI
on MS-related Fatigue; Data from Observational TOP Study Evaluate
Long-term Safety and Efficacy in Clinical Setting -
-- Updates to the First Risk Stratification Algorithm That Uses
Safety Biomarker to Inform Treatment Decisions in MS --
WESTON, Mass. & DUBLIN, Apr 26, 2012 (BUSINESS WIRE) --Biogen
Idec (NASDAQ: BIIB) and Elan
Corporation, plc (NYSE: ELN... |
|
12 April 2012
Elan Announces Webcast of First Quarter 2012 Financial Results| DUBLIN, Apr 12, 2012 (BUSINESS WIRE) --Elan Corporation, plc (NYSE: ELN) announced today that it will host a
conference call on Thursday, April 26, 2012 at 8:30 a.m. Eastern Time
(ET), 1:30 p.m. British Summer Time (BST) with the investment community
to discuss Elan's first quarter 2012 financial results, which will be
released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over
th... |
|
13 March 2012
Elan Raises $381 Million in Sale of 76% of Alkermes Holding| DUBLIN--(BUSINESS WIRE)--Mar. 13, 2012--
Elan Corporation, plc (NYSE: ELN) today raised approximately $381
million in net proceeds from the sale of 76% (24.15 million ordinary
shares) of its shareholding in Alkermes plc (NASDAQ: ALKS), net of
underwriter fees. These proceeds further strengthen Elan’s cash balances
and capital structure.
In September 2011, when Elan combined its Elan Drug Technology (EDT)
business with Alkermes Inc, Ela... |
|
01 March 2012
Elan Chairman Provides Update on CEO Succession| DUBLIN--(BUSINESS WIRE)--Mar. 1, 2012--
The Chairman of Elan (NYSE:ELN), Mr. Robert Ingram today provided an
update on CEO succession:
“On June 3, 2010, Elan communicated that, as part of its prudent
executive succession management process, Kelly Martin, CEO, and the
Board of Directors agreed that by May 1, 2012, Kelly would have
successfully completed his commitment and overall duty as CEO to the
company that he had served since Janua... |
|
23 February 2012
Elan Announces Filing of Annual Report on Form 20-F for Year Ended December 31, 2011| DUBLIN -- (BUSINESS WIRE) -- Feb. 23, 2012 -- Elan Corporation, plc (NYSE: ELN) today announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2011. The Form 20-F is available on Elan's website at http://www.elan.com. Elan will provide to all holders of Elan securities, upon request and free of charge, a hard copy of our complete audited financial statements included in our Form 20-F.
About Elan Corporation, plc
Elan Corporation, plc is a neuroscience-foc... |
|
21 February 2012
Elan to Present at Cowen & Co., 32nd Annual Healthcare Conference| DUBLIN--(BUSINESS WIRE)--Feb. 21, 2012--
Elan Corporation, plc (NYSE: ELN) announced today that it will present
at the Cowen & Co., 32nd Annual Healthcare Conference on
Tuesday, March 6, 2012 at 9.20 a.m. Eastern Standard Time and 2.20 p.m.
Greenwich Mean Time.
Interested parties may access a live audio webcast of the presentation
by visiting the Investor Relations section of the Elan website at http://www.elan.com,
then clicking o... |
|
08 February 2012
Elan Reports Fourth Quarter and Full-Year 2011 Financial Results|
Revenues ex-EDT up 19% over full-year 2010 to $1,068 million; Debt
reduced by 51%
Label updates advance Tysabri risk-stratification
2012 Guidance: Revenues $1.2-1.25 billion; Adjusted EBITDA of at
least $200 million
DUBLIN--(BUSINESS WIRE)--Feb. 8, 2012--
Elan Corporation, plc today reported its fourth quarter and full-year
2011 financial results.
“In 2011, Elan m... |
|
01 February 2012
Elan to Present at the Leerink Swann 2012 Global Healthcare Conference| DUBLIN--(BUSINESS WIRE)--Feb. 1, 2012--
Elan Corporation, plc (NYSE:ELN) announced today that it will present at
the Leerink Swann 2012 Global Healthcare Conference on Wednesday
February 15, 2012 at 2.00 p.m. Eastern Standard Time and 7.00 p.m.
Greenwich Mean Time.
Interested parties may access a live audio webcast of the presentation
by visiting the Investor Relations section of the Elan website at http://www.elan.com,
then clicking o... |
|
26 January 2012
ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis| WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Jan. 26, 2012--
Biogen
Idec (NASDAQ: BIIB) and Elan
Corporation, plc (NYSE: ELN) today announced a global Phase 3b
study, ASCEND, that is being conducted to evaluate the effectiveness of
TYSABRI as a treatment for secondary-progressive multiple sclerosis
(SPMS). According to the National Multiple Sclerosis Society,
approximately half of all people initially diagnosed with
relapsing-remitting mult... |
|
25 January 2012
Elan Announces Webcast of Fourth Quarter and Full-Year 2011 Financial Results| DUBLIN--(BUSINESS WIRE)--Jan. 25, 2012-- Elan Corporation, plc (NYSE:ELN) announced today that it will host a conference call on Wednesday, February 8, 2012 at 8:30 a.m. Eastern Standard Time (EST), 1:30 p.m. Greenwich Mean Time (GMT) with the investment community to discuss Elan’s fourth quarter and full-year 2011 financial results, which will be released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over the Internet a... |
|
20 January 2012
FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor| WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Jan. 20, 2012-- Today Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JCV antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal leukoence... |
|
RSS Feeds | 
E-mail Alerts | 
Contact IR